+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuroprotective"

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Cannabinoid Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Cannabinoid Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
Parkinsons Disease Market - Product Thumbnail Image

Parkinsons Disease Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

The Neuroprotective market is a subset of Central Nervous System (CNS) drugs that are designed to protect the brain and spinal cord from damage caused by disease, trauma, or other conditions. Neuroprotective drugs are used to treat a variety of neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury. These drugs can also be used to reduce the risk of developing these conditions. Neuroprotective drugs work by reducing inflammation, improving blood flow, and protecting neurons from damage. Neuroprotective drugs are an important part of treating neurological disorders, as they can help reduce the severity of symptoms and improve quality of life. They are also used to prevent further damage to the brain and spinal cord. Some companies in the Neuroprotective market include AbbVie, AstraZeneca, Biogen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more